AB
RIGL icon

Amalgamated Bank’s Rigel Pharmaceuticals RIGL Stock Holding History

Amalgamated Bank’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-554
Closed -$24K – 2567
2025
Q4 		$24K Sell
554
-34
-6% -$1.28K ﹤0.01% 2037
2025
Q3 		$17K Hold
588
– – ﹤0.01% 2208
2025
Q2 		$11K Hold
588
– – ﹤0.01% 2407
2025
Q1 		$11K Hold
588
– – ﹤0.01% 2339
2024
Q4 		$10K Hold
588
– – ﹤0.01% 2443
2024
Q3 		$10K Hold
588
– – ﹤0.01% 2473
2024
Q2 		$5K Hold
588
– – ﹤0.01% 2796
2024
Q1 		$9K Sell
588
-1,677
-74% -$22.6K ﹤0.01% 2497
2023
Q4 		$33K Sell
2,265
-175
-7% -$1.79K ﹤0.01% 2424
2023
Q3 		$26K Hold
2,440
– – ﹤0.01% 2533
2023
Q2 		$31K Buy
2,440
+46
+2% +$622 ﹤0.01% 2516
2023
Q1 		$32K Sell
2,394
-362
-13% -$5.75K ﹤0.01% 2481
2022
Q4 		$41K Hold
2,756
– – ﹤0.01% 2513
2022
Q3 		$33K Buy
2,756
+44
+2% +$595 ﹤0.01% 2640
2022
Q2 		$31K Sell
2,712
-70
-3% -$1.41K ﹤0.01% 2705
2022
Q1 		$83K Sell
2,782
-235
-8% -$6.36K ﹤0.01% 2271
2021
Q4 		$80K Sell
3,017
-44
-1% -$1.33K ﹤0.01% 2083
2021
Q3 		$111K Sell
3,061
-166
-5% -$6.53K ﹤0.01% 2069
2021
Q2 		$140K Buy
3,227
+591
+22% +$22.3K ﹤0.01% 2077
2021
Q1 		$90K Hold
2,636
– – ﹤0.01% 1558
2020
Q4 		$92K Buy
2,636
+8
+0.3% +$232 ﹤0.01% 1531
2020
Q3 		$63K Sell
2,628
-60
-2% -$1.47K ﹤0.01% 1443
2020
Q2 		$49K Sell
2,688
-269
-9% -$4.84K ﹤0.01% 1450
2020
Q1 		$46K Sell
2,957
-14
-0.5% -$298 ﹤0.01% 1578
2019
Q4 		$64K Buy
2,971
+24
+0.8% +$494 ﹤0.01% 1775
2019
Q3 		$55K Sell
2,947
-24
-0.8% -$496 ﹤0.01% 1704
2019
Q2 		$78K Buy
2,971
+414
+16% +$9.34K ﹤0.01% 1713
2019
Q1 		$66K Buy
2,557
+88
+4% +$2.01K ﹤0.01% 1629
2018
Q4 		$57K Buy
2,469
+1,388
+128% +$39.2K ﹤0.01% 1557
2018
Q3 		$35K Sell
1,081
-1,398
-56% -$42K ﹤0.01% 1427
2018
Q2 		$70K Buy
2,479
+513
+26% +$18.3K ﹤0.01% 1677
2018
Q1 		$70K Sell
1,966
-44
-2% -$1.76K ﹤0.01% 1549
2017
Q4 		$78K Buy
2,010
+407
+25% +$15.5K ﹤0.01% 1584
2017
Q3 		$41K Buy
1,603
+128
+9% +$3.11K ﹤0.01% 1560
2017
Q2 		$40K Buy
1,475
+43
+3% +$1.18K ﹤0.01% 1554
2017
Q1 		$47K Buy
1,432
+199
+16% +$5.07K ﹤0.01% 1471
2016
Q4 		$29K Buy
+1,233
New +$35.3K ﹤0.01% 1502

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Bank's RIGL Position: Q1 2026 in Review

Amalgamated Bank sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 554 shares — an estimated $24K sold.

Amalgamated Bank first reported a position in RIGL in Q4 2016 and held it in 37 quarters. The position peaked at $140K in Q2 2021. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Amalgamated Bank reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 554 Rigel Pharmaceuticals shares in Q1 2026, an estimated $24K.
  • Amalgamated Bank first reported a position in Rigel Pharmaceuticals in Q4 2016 and held it in 37 quarters.
  • Amalgamated Bank's Rigel Pharmaceuticals position peaked at $140K in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.